2020 ASCO Virtual Direct™ Highlights


 

2020 ASCO Update on HER2+ mCRC: Did Trastuzumab Deruxtecan Demonstrate Activity in Patients With HER2-Expressing Disease Who Are Refractory to Standard Therapies?

140 views
August 20, 2020
Comments 0
Login to view comments. Click here to Login